Follow the people · Insider
Pablo J. Cagnoni
Pablo J. Cagnoni files insider transactions with the SEC as a president, global head of r&d of Incyte (INCY). We hold 7 disclosed purchases and sales filed since 15 December 2006, 4 of them in the last 90 days.
- Files forINCY
- Disclosed buys and sells7 in all, 4 in the last 90 days
- Last disclosure20 August 2026
Positions held
7 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 5 June 2023 — 19 August 2026President, Global Head of R&D · Incyte (INCY)53 Form 4 lines · source: SEC Form 4
- Filed 25 June 2020 — 4 June 2024Director · Fusion Pharmaceuticals (FUSN)9 Form 4 lines · source: SEC Form 4
- Filed 31 October 2018 — 1 February 2023CEO and President · Rubius Therapeutics (RUBY)20 Form 4 lines · source: SEC Form 4
- Filed 18 October 2016 — 19 November 2019Director · CRISPR Therapeutics AG (CRSP)19 Form 4 lines · source: SEC Form 4
- Filed 11 March 2013 — 1 October 2013EVP, Global R&D and Tech Ops · Onyx Pharmaceuticals (ONXX)4 Form 4 lines · source: SEC Form 4
- Filed 19 March 2007 — 30 September 2009Sr. VP, Chief Medical Officer · Allos Therapeutics (ALTH)9 Form 4 lines · source: SEC Form 4
- Filed 13 December 2006 — 13 December 2006VP & Chief Medical Officer · Osi Pharmaceuticals (OSIP)1 Form 4 line · source: SEC Form 4
Everything they disclosed
115 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 10,801 shares of IncyteSEC Form 420 August 2026Common Stock · traded 19 August 2026 · filed 20 August 2026
- ▼ sold on the open market 10,803 shares of IncyteSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 10,640 shares of IncyteSEC Form 47 August 2026Common Stock · traded 5 August 2026 · filed 7 August 2026
- ▼ sold on the open market 15,888 shares of IncyteSEC Form 44 August 2026Common Stock · traded 31 July 2026 · filed 4 August 2026
- was granted 13,403 shares of IncyteSEC Form 420 July 2026Common Stock · traded 16 July 2026 · filed 20 July 2026
- was granted 33,508 shares of Incyte (a derivative holding)SEC Form 420 July 2026Performance Shares · traded 16 July 2026 · filed 20 July 2026
- was granted 57,861 shares of Incyte (a derivative holding)SEC Form 420 July 2026Employee Stock Option (right to buy) · traded 16 July 2026 · filed 20 July 2026
- had shares withheld for tax on 17,969 shares of IncyteSEC Form 416 July 2026Common Stock · traded 14 July 2026 · filed 16 July 2026
- had shares withheld for tax on 4,950 shares of IncyteSEC Form 416 July 2026Common Stock · traded 15 July 2026 · filed 16 July 2026
- had shares withheld for tax on 25,469 shares of IncyteSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- was granted 31,517 shares of IncyteSEC Form 420 May 2026Common Stock · traded 6 May 2026 · filed 20 May 2026
- exercised options over 6,077 shares of IncyteSEC Form 421 April 2026Common Stock · traded 17 April 2026 · filed 21 April 2026
- exercised options over 12,590 shares of IncyteSEC Form 421 April 2026Common Stock · traded 17 April 2026 · filed 21 April 2026
- ▼ sold on the open market 18,667 shares of IncyteSEC Form 421 April 2026Common Stock · traded 17 April 2026 · filed 21 April 2026
- exercised options over 6,077 shares of Incyte (a derivative holding)SEC Form 421 April 2026Employee Stock Option (right to buy) · traded 17 April 2026 · filed 21 April 2026
- exercised options over 12,590 shares of Incyte (a derivative holding)SEC Form 421 April 2026Employee Stock Option (right to buy) · traded 17 April 2026 · filed 21 April 2026
- was granted 27,892 shares of IncyteSEC Form 417 April 2026Common Stock · traded 15 April 2026 · filed 17 April 2026
- exercised options over 7,166 shares of IncyteSEC Form 419 March 2026Common Stock · traded 17 March 2026 · filed 19 March 2026
- exercised options over 11,501 shares of IncyteSEC Form 419 March 2026Common Stock · traded 17 March 2026 · filed 19 March 2026
- ▼ sold on the open market 18,667 shares of IncyteSEC Form 419 March 2026Common Stock · traded 17 March 2026 · filed 19 March 2026
- exercised options over 7,166 shares of Incyte (a derivative holding)SEC Form 419 March 2026Employee Stock Option (right to buy) · traded 17 March 2026 · filed 19 March 2026
- exercised options over 11,501 shares of Incyte (a derivative holding)SEC Form 419 March 2026Employee Stock Option (right to buy) · traded 17 March 2026 · filed 19 March 2026
- exercised options over 7,166 shares of Incyte (a derivative holding)SEC Form 419 March 2026Employee Stock Option (right to buy) · traded 17 March 2026 · filed 19 March 2026
- exercised options over 11,501 shares of Incyte (a derivative holding)SEC Form 419 March 2026Employee Stock Option (right to buy) · traded 17 March 2026 · filed 19 March 2026
- exercised options over 7,166 shares of IncyteSEC Form 419 March 2026Common Stock · traded 17 March 2026 · filed 19 March 2026
- exercised options over 11,501 shares of IncyteSEC Form 419 March 2026Common Stock · traded 17 March 2026 · filed 19 March 2026
- ▼ sold on the open market 18,667 shares of IncyteSEC Form 419 March 2026Common Stock · traded 17 March 2026 · filed 19 March 2026
- exercised options over 13,093 shares of IncyteSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- exercised options over 5,575 shares of IncyteSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 18,668 shares of IncyteSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- exercised options over 13,093 shares of Incyte (a derivative holding)SEC Form 423 February 2026Employee Stock Option (right to buy) · traded 19 February 2026 · filed 23 February 2026
- exercised options over 5,575 shares of Incyte (a derivative holding)SEC Form 423 February 2026Employee Stock Option (right to buy) · traded 19 February 2026 · filed 23 February 2026
- exercised options over 13,093 shares of Incyte (a derivative holding)SEC Form 423 February 2026Employee Stock Option (right to buy) · traded 19 February 2026 · filed 23 February 2026
- exercised options over 5,575 shares of Incyte (a derivative holding)SEC Form 423 February 2026Employee Stock Option (right to buy) · traded 19 February 2026 · filed 23 February 2026
- exercised options over 13,093 shares of IncyteSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- exercised options over 5,575 shares of IncyteSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 18,668 shares of IncyteSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- was granted 28,475 shares of Incyte (a derivative holding)SEC Form 421 January 2026Employee Stock Option (right to buy) · traded 16 January 2026 · filed 21 January 2026
- was granted 28,475 shares of Incyte (a derivative holding)SEC Form 421 January 2026Employee Stock Option (right to buy) · traded 16 January 2026 · filed 21 January 2026
- was granted 43,846 shares of Incyte (a derivative holding)SEC Form 416 July 2025Performance Shares · traded 15 July 2025 · filed 16 July 2025
- was granted 39,471 shares of Incyte (a derivative holding)SEC Form 416 July 2025Employee Stock Option (right to buy) · traded 15 July 2025 · filed 16 July 2025
- had shares withheld for tax on 1,280 shares of IncyteSEC Form 416 July 2025Common Stock · traded 14 July 2025 · filed 16 July 2025
- had shares withheld for tax on 2,628 shares of IncyteSEC Form 416 July 2025Common Stock · traded 15 July 2025 · filed 16 July 2025
- was granted 17,538 shares of IncyteSEC Form 416 July 2025Common Stock · traded 15 July 2025 · filed 16 July 2025
- was granted 40,289 shares of Incyte (a derivative holding)SEC Form 422 January 2025Employee Stock Option (right to buy) · traded 17 January 2025 · filed 22 January 2025
- was granted 44,411 shares of Incyte (a derivative holding)SEC Form 417 July 2024Employee Stock Option (right to buy) · traded 15 July 2024 · filed 17 July 2024
- was granted 19,851 shares of IncyteSEC Form 417 July 2024Common Stock · traded 15 July 2024 · filed 17 July 2024
- had shares withheld for tax on 749 shares of IncyteSEC Form 417 July 2024Common Stock · traded 15 July 2024 · filed 17 July 2024
- returned to the issuer 30,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- returned to the issuer 141,011 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- was granted 21,843 shares of Incyte (a derivative holding)SEC Form 422 January 2024Employee Stock Option (right to buy) · traded 18 January 2024 · filed 22 January 2024
- was granted 20,275 shares of Incyte (a derivative holding)SEC Form 418 July 2023Employee Stock Option (right to buy) · traded 14 July 2023 · filed 18 July 2023
- was granted 9,668 shares of IncyteSEC Form 418 July 2023Common Stock · traded 14 July 2023 · filed 18 July 2023
- was granted 192,400 shares of IncyteSEC Form 421 June 2023Common Stock · traded 5 June 2023 · filed 21 June 2023
- was granted 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 414 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 14 June 2023
- was granted 179,613 shares of IncyteSEC Form 47 June 2023Common Stock · traded 5 June 2023 · filed 7 June 2023
- ▼ sold on the open market 8,448 shares of Rubius TherapeuticsSEC Form 41 February 2023Common Stock · traded 1 February 2023 · filed 1 February 2023
- exercised options over 21,250 shares of Rubius Therapeutics (a derivative holding)SEC Form 431 January 2023Restricted Stock Units · traded 29 January 2023 · filed 31 January 2023
- exercised options over 25,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 431 January 2023Restricted Stock Units · traded 31 January 2023 · filed 31 January 2023
- exercised options over 21,250 shares of Rubius TherapeuticsSEC Form 431 January 2023Common Stock · traded 29 January 2023 · filed 31 January 2023
- exercised options over 25,000 shares of Rubius TherapeuticsSEC Form 431 January 2023Common Stock · traded 31 January 2023 · filed 31 January 2023
- ▼ sold on the open market 7,240 shares of Rubius TherapeuticsSEC Form 431 January 2023Common Stock · traded 31 January 2023 · filed 31 January 2023
- was granted 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 422 June 2022Stock Option (Right to Buy) · traded 14 June 2022 · filed 22 June 2022
- gave away 4,000 shares of Rubius TherapeuticsSEC Form 414 February 2022Common Stock · traded 26 April 2021 · filed 14 February 2022
- gave away 2,200 shares of Rubius TherapeuticsSEC Form 414 February 2022Common Stock · traded 16 June 2021 · filed 14 February 2022
- exercised options over 21,250 shares of Rubius Therapeutics (a derivative holding)SEC Form 41 February 2022Restricted Stock Units · traded 29 January 2022 · filed 1 February 2022
- was granted 365,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 41 February 2022Stock Option (Right to Buy) · traded 31 January 2022 · filed 1 February 2022
- was granted 100,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 41 February 2022Restricted Stock Units · traded 31 January 2022 · filed 1 February 2022
- exercised options over 21,250 shares of Rubius TherapeuticsSEC Form 41 February 2022Common Stock · traded 29 January 2022 · filed 1 February 2022
- ▼ sold on the open market 6,730 shares of Rubius TherapeuticsSEC Form 41 February 2022Common Stock · traded 1 February 2022 · filed 1 February 2022
- was granted 17,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 47 June 2021Stock Option (Right to Buy) · traded 4 June 2021 · filed 7 June 2021
- was granted 375,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 42 February 2021Stock Option (Right to Buy) · traded 29 January 2021 · filed 2 February 2021
- was granted 85,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 42 February 2021Restricted Stock Units · traded 29 January 2021 · filed 2 February 2021
- was granted 30,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 430 June 2020Stock Option (Right to Buy) · traded 25 June 2020 · filed 30 June 2020
- ▲ bought on the open market 21,000 shares of Rubius TherapeuticsSEC Form 415 April 2020Common Stock · traded 14 April 2020 · filed 15 April 2020
- was granted 500,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 43 February 2020Stock Option (Right to Buy) · traded 31 January 2020 · filed 3 February 2020
- exercised options over 7,500 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 421 November 2019Stock Option (Right to Buy) · traded 19 November 2019 · filed 21 November 2019
- exercised options over 7,500 shares of CRISPR Therapeutics AGSEC Form 421 November 2019Common Shares · traded 19 November 2019 · filed 21 November 2019
- ▼ sold on the open market 7,500 shares of CRISPR Therapeutics AGSEC Form 421 November 2019Common Shares · traded 19 November 2019 · filed 21 November 2019
- exercised options over 7,500 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 413 November 2019Stock Option (Right to Buy) · traded 12 November 2019 · filed 13 November 2019
- exercised options over 7,500 shares of CRISPR Therapeutics AGSEC Form 413 November 2019Common Shares · traded 12 November 2019 · filed 13 November 2019
- ▼ sold on the open market 7,500 shares of CRISPR Therapeutics AGSEC Form 413 November 2019Common Shares · traded 12 November 2019 · filed 13 November 2019
- exercised options over 7,500 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 41 November 2019Stock Option (Right to Buy) · traded 30 October 2019 · filed 1 November 2019
- exercised options over 7,500 shares of CRISPR Therapeutics AGSEC Form 41 November 2019Common Shares · traded 30 October 2019 · filed 1 November 2019
- ▼ sold on the open market 7,500 shares of CRISPR Therapeutics AGSEC Form 41 November 2019Common Shares · traded 30 October 2019 · filed 1 November 2019
- was granted 15,000 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 413 June 2019Stock Option (Right to Buy) · traded 11 June 2019 · filed 13 June 2019
- was granted 100,000 shares of Rubius Therapeutics (a derivative holding)SEC Form 44 February 2019Stock Option (Right to Buy) · traded 31 January 2019 · filed 4 February 2019
- was granted 164,400 shares of Rubius Therapeutics (a derivative holding)SEC Form 41 November 2018Stock Option (Right to Buy) · traded 31 October 2018 · filed 1 November 2018
- was granted 193,400 shares of Rubius Therapeutics (a derivative holding)SEC Form 41 November 2018Stock Option (Right to Buy) · traded 31 October 2018 · filed 1 November 2018
- exercised options over 5,816 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 45 July 2018Stock Option (Right to Buy) · traded 3 July 2018 · filed 5 July 2018
- exercised options over 1,684 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 45 July 2018Stock Option (Right to Buy) · traded 5 July 2018 · filed 5 July 2018
- exercised options over 5,816 shares of CRISPR Therapeutics AGSEC Form 45 July 2018Common Shares · traded 3 July 2018 · filed 5 July 2018
- ▼ sold on the open market 5,816 shares of CRISPR Therapeutics AGSEC Form 45 July 2018Common Shares · traded 3 July 2018 · filed 5 July 2018
- exercised options over 1,684 shares of CRISPR Therapeutics AGSEC Form 45 July 2018Common Shares · traded 5 July 2018 · filed 5 July 2018
- ▼ sold on the open market 1,684 shares of CRISPR Therapeutics AGSEC Form 45 July 2018Common Shares · traded 5 July 2018 · filed 5 July 2018
- was granted 15,000 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 415 June 2018Stock Option (Right to Buy) · traded 15 June 2018 · filed 15 June 2018
- was granted 15,000 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 42 June 2017Stock Option (Right to Buy) · traded 31 May 2017 · filed 2 June 2017
- was granted 15,000 shares of CRISPR Therapeutics AG (a derivative holding)SEC Form 420 October 2016Stock Option (Right to Buy) · traded 18 October 2016 · filed 20 October 2016
- returned to the issuer 34,030 shares of Onyx Pharmaceuticals (a derivative holding)SEC Form 43 October 2013Stock Options · traded 1 October 2013 · filed 3 October 2013
- returned to the issuer 16,257 shares of Onyx PharmaceuticalsSEC Form 43 October 2013Common Stock · traded 1 October 2013 · filed 3 October 2013
- was granted 34,030 shares of Onyx Pharmaceuticals (a derivative holding)SEC Form 413 March 2013Stock Option (Right to Buy) · traded 11 March 2013 · filed 13 March 2013
- was granted 16,257 shares of Onyx PharmaceuticalsSEC Form 413 March 2013Common Stock · traded 11 March 2013 · filed 13 March 2013
- returned to the issuer 61,373 shares of Allos TherapeuticsSEC Form 42 October 2009Common Stock · traded 30 September 2009 · filed 2 October 2009
- ▼ sold on the open market 6,200 shares of Allos TherapeuticsSEC Form 420 March 2009Common Stock · traded 20 March 2009 · filed 20 March 2009
- was granted 143,452 shares of Allos Therapeutics (a derivative holding)SEC Form 425 February 2009Stock Options (Right to Buy) · traded 23 February 2009 · filed 25 February 2009
- was granted 23,873 shares of Allos TherapeuticsSEC Form 425 February 2009Common Stock · traded 23 February 2009 · filed 25 February 2009
- ▼ sold on the open market 3,000 shares of Allos TherapeuticsSEC Form 420 March 2008Common Stock · traded 20 March 2008 · filed 20 March 2008
- ▼ sold on the open market 3,100 shares of Allos TherapeuticsSEC Form 420 March 2008Common Stock · traded 20 March 2008 · filed 20 March 2008
- was granted 150,000 shares of Allos Therapeutics (a derivative holding)SEC Form 427 February 2008Stock Options (Right to buy) · traded 25 February 2008 · filed 27 February 2008
- was granted 300,000 shares of Allos Therapeutics (a derivative holding)SEC Form 420 March 2007Stock Options (Right to buy) · traded 19 March 2007 · filed 20 March 2007
- was granted 75,000 shares of Allos TherapeuticsSEC Form 420 March 2007Common Stock · traded 19 March 2007 · filed 20 March 2007
- was granted 6,700 shares of Osi PharmaceuticalsSEC Form 415 December 2006Common Stock · traded 13 December 2006 · filed 15 December 2006
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.